Characterization of TP53 mutations in low‐grade myelodysplastic syndromes and myelodysplastic syndromes with a non‐complex karyotype
- 20 October 2017
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 99 (6) , 536-543
Abstract
Objectives: Although commonly associated with high‐grade myelodysplastic syndrome (MDS) and MDS with a complex karyotype, TP53 mutations also occur in low‐grade MDS and MDS with a non‐complex karyotype. In latter cases, their clinicopathological features and the characteristics of TP53 mutations remain poorly characterized.Methods: 176 MDS cases with TP53 mutations were stratified and characterized based on their karyotype and histologic subtype.Results: Among 176 cases, 17% had a non‐complex karyotype and 24% were low‐grade MDS. TP53 mutations often occurred in DNA‐binding domains and the majority of cases had only one mutation, irrespective of their karyotype and MDS subtype. The variant allele frequency (VAF), however, was associated with karyotype complexity and the types of MDS with a lower VAF found in cases with a non‐complex karyotype and low‐grade MDS. A low (TP53 mutations showed a lower VAF. Patients with a lower VAF had a better survival. TP53 mutations are not the only prognostic factor in MDS patients with TP53 mutations as the VAF, blast counts and history of prior therapy also play important roles in prognosis.Keywords
This publication has 29 references indexed in Scilit:
- Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemiaHaematologica, 2013
- TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosisBritish Journal of Haematology, 2013
- Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic SyndromesJournal of Clinical Oncology, 2012
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Mutant p53: one name, many proteinsGenes & Development, 2012
- Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patientsLeukemia, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of TumorigenesisGenes & Cancer, 2011
- Therapy-Related Myelodysplastic Syndrome: Models and GeneticsTransplantation and Cellular Therapy, 2010
- Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancerOncogene, 1998